Monday, December 09, 2019

Tumor Treating Fields—a review and graphic

Treatment for glioblastoma approved in 2015.

“In 2011, the United States Food and Drug Administration (FDA) approved a tumor treating fields (TTF) device for treatment of recurrent or refractory GBM. More recently, the FDA approved the TTF device as adjuvant treatment for newly-diagnosed patients after completing standard-of-care surgery and chemoradiation. The National Comprehensive Cancer Network (NCCN) added the TTF device as an option for treatment of newly-diagnosed GBM. Despite FDA approval, skepticism remains regarding this therapy. In this review we discuss the current evidence supporting treatment with the TTF device and its limitations.”

TT Fields Treatment

  • The TT fields treatment device is portable and may help people treat their cancer while continuing their normal activities.
  • People undergoing TT fields therapy use small transducers that are attached to their head with adhesive bandages. Hair must be shaved in order to use the device.
  • The transducers are connected to wires, which are plugged into a battery that is about the size of a book. The batteries fit into a bag that the person carries with them, either in a backpack, across the body, or over the shoulder like a messenger bag.
  • The system comes with multiple batteries and a charging station. The user is alerted when batteries need to be changed.
  • The therapy is continual, but people can unplug the device for short times

No comments: